TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in National Institutes of Health (NIH) Toolbox Effortful Control (EC) Composite Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Clinical Global Impressions -Severity and Improvement Scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: slope of slow wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amplitude of slow wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of slow wave
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ALSFRS-R scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and Behavioral Scale (CAS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of hCTMSCs
Endpoint domain: Adverse events/effects
Primary endpoint: Infusional toxicity of the cell product
Endpoint domain: Adverse events/effects
Primary endpoint: ROS concentrations in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time of first analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of analgesic used within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiota at 42 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in gut microbiota at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of mammograms completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tumor detection rate of white light cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor detection rate of Bladder-PAD cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor false detection rate of white light cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor false detection rate of Bladder-PAD cystoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all-cause hospital readmission or all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Wound Complication events
Endpoint domain: Adverse events/effects
Primary endpoint: Fascial Dehiscence Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cultural-Social Engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Cumulative incidence of potential hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score in multiple-choice-test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in follow-up images compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events analysis
Endpoint domain: Adverse events/effects
Primary endpoint: Presence or absence of otoconia in the posterior semicircular canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straight Leg Raise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of subjects with adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in CD8+ cell infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin a1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neurophysiological characterization of dopaminergic neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biochemical characterization of dopaminergic neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-synuclein misfolding in dopaminergic neurons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with severe disease
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge at the end of educational workshops completion
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitude towards Smoking Cannabis at the end of educational workshops completion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitude towards drugs trafficking at the end of educational workshops completion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: length of the resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in Prostate Specific Antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Urinary Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in PTSD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Anxiety Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in Antisocial Behavior Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Aggressive Behavior Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure pain threshold on navel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unpleasantness of pressure pain threshold on navel
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ventilator-free days to day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of treatment for non-genital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of treatment (side effects)
Endpoint domain: Adverse events/effects
Primary endpoint: Global scores on the BRIEF questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: analgesic drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: severity of early postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve of Milvexian from Time Zero to Infinity (AUC [0-Infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Analyte Concentration (Cmax) of Milvexian
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual Sampling Time to Reach the Maximum Observed Analyte Concentration (Tmax) of Milvexian
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the level of perceived work ability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to primary healing of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to total healing of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average step cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Emergent Adverse Events (TEAEs) by Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Grade 3, 4 and 5 TEAEs by Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Number of TEAEs Related to TT-702 and/or Darolutamide by Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiographic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-SSRS
Endpoint domain: Adverse events/effects
Primary endpoint: Sperm membrane potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sperm intracellular Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with solicited local reactions at the injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who experience at least one unsolicited Treatment-emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Arterial Pressure < 65mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of EUS-guided treatment for varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of copy number variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single-leg balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arterial oxygen saturation (Sao2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported levels of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abnormal structural heart findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abnormal electrocardiography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk factors associated with cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of LH of ≤ 3 IU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Implementation Assessment Measure
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of treatment related mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Increase in antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rapid secondary recall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of VX-993
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of VX-993
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission proportion
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Degree of cartilage wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Post-stroke depression severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reported Tinnitus Relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fetuin-A serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver stiffness degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Clinical Benefit (DoCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of cesarean scar niche
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in seric lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum levels of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum levels of inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Standardized uptake value (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite complete response rate (CCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Falls Efficacy Scale (FES)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in the Mini-BESTest Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of actively detected local and systemic AEs (Stage I)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of actively detected local and systemic AEs (Stage II)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in geometric mean titers of antibodies to N-protein of SARS-CoV-2 (Stage II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in weight-loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ambulatory blood pressure monitoring (ABPM) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 1-year CNS progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Post-treatment clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMV PCR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAL antigen-specific Th1 and Th17 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FVC relative change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Bacteroidetes in Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage Change in Firmicutes in Stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intubation of terminal ileum and cecum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change in Nail Biting Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in Vitamin D status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Iron status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genetic Counseling Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in cardio-metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in urinary and plasma metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in mitochondrial DNA methylation and circulating miRNAs expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in heart rate variability (HVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in saliva cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in visual analogue stress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sustainable Nutrition Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Nutrition Behavior Change Stage
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Visual Analogue Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of hemodynamically significant stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal clot firmness (MCF) of EXTEM assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of life as measured by FACT-B
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in emotional functioning scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Effectiveness of Pit and Fissure Sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of Pit and Fissure Sealants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progress of urea / creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Aesthetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Meaning and Purpose
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients free of serious treatment related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of clinically significant depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neutrophil-to-lymphocyte ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peritoneal-free survival
Endpoint domain: Mortality/survival
Primary endpoint: rate of relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potentials (VEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accumulation velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secretion velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of definite anxiety cases
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of definite depression cases
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with ≥50% decrease in PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of pathological uptake on the prosthetic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consistency in identifying cervical CT features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steroid free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation from baseline of systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional status after Pulmonary Rehabilitation Program
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exercise capacity after Pulmonary Rehabilitation Program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of VTE events
Endpoint domain: Adverse events/effects
Primary endpoint: Programmed death-1 (PD-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Programmed death ligand -1 (PDL-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with DLT
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Midazolam dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: EuroQoL (EQ-5D-3L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Central blood pressure and pulse wave variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain in surgeons after operating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in maternal pH from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean umbilical blood pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the mechanical decongestant seawater spray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes